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INTRODUCTION
Adenosine 5′-monophosphate (AMP)-
activated protein kinase (AMPK) is a het-
erotrimeric serine/threonine kinase con-
sisting of a catalytic α subunit and β and
γ regulatory subunits. All three subunits
of AMPK are necessary for the formation
of a fully active complex (1,2). Classi-
cally, activation of AMPK has been de-
scribed to occur under conditions of cel-
lular stress that affect the balance be-
tween cellular adenosine 5′-triphosphate
(ATP), adenosine 5′-diphosphate (ADP)
and AMP and involves direct binding of
AMP and ADP to the AMPK γ subunit,
which then results in phosphorylation of
Thr172 within the AMPK α activating
loop (3–8). Recent studies have shown
that exposure of cells to reactive oxygen
species or glycogen can induce AMPK
activation independently of changes in
cellular ATP-to-AMP ratios (9,10).
Although AMPK has primarily been
characterized as a major regulator of
M O L  M E D  1 8 : 6 5 9 - 6 6 8 ,  2 0 1 2  |  T A D I E  E T  A L .  |  6 5 9
Toll-Like Receptor 4 Engagement Inhibits Adenosine
5′-Monophosphate–Activated Protein Kinase Activation
through a High Mobility Group Box 1 Protein–Dependent
Mechanism
Jean-Marc Tadie,1,2* Hong-Beom Bae,1,3* Jessy S Deshane,1 Celeste P Bell,1 Eduardo R Lazarowski,4
David D Chaplin,5 Victor J Thannickal,1 Edward Abraham,6 and Jaroslaw W Zmijewski1
1Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America; 2Service de
Réanimation Médicale, Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris, Paris, France; 3Department of
Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea; 4Department of
Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; 5Department
Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America; and 6Wake Forest School of
Medicine, Winston-Salem, North Carolina, United States of America
Despite the potent antiinflammatory effects of pharmacologically induced adenosine 5′-monophosphate kinase (AMPK)
activation on Toll-like receptor 4 (TLR4)-induced cellular activation, there is little evidence that AMPK is activated during in-
flammatory conditions. In the present studies, we examined mechanisms by which TLR4 engagement may affect the ability of
AMPK to become activated in neutrophils and macrophages under in vitro conditions and in the lungs during lipopolysac-
charide (LPS)-induced acute lung injury. We found that incubation of neutrophils or macrophages with LPS diminished the abil-
ity of 5-aminoimidazole-4- carboxamide-1-β-D-ribofuranoside (AICAR) or hydrogen peroxide (H2O2) to activate AMPK. Although ra-
tios of AMP to adenosine 5′-triphosphate (ATP) were increased in LPS-treated neutrophils and in the lungs of LPS exposed mice, a
condition that should result in AMPK activation, no activation of AMPK was found. Immunocytochemistry and Western blot anal-
ysis revealed that nuclear to cytosolic translocation of the proinflammatory mediator high mobility group box 1 protein (HMGB1)
correlated with inhibition of AMPK activation in LPS-stimulated macrophages. Moreover, while induced overexpression of HMGB1
resulted in inhibition of AMPK activation, Small interfering RNA (siRNA)-induced knockdown of HMGB1 was associated with en-
hanced activation of AMPK in macrophages incubated with AICAR. Increased interaction between liver kinase B1 (LKB1), an up-
stream activator of AMPK, and HMGB1 was found in LPS-stimulated macrophages and in the lungs of mice exposed to LPS. These
results suggest that nuclear to cytoplasmic translocation of HMGB1 in TLR4-activated cells potentiates inflammatory responses by
binding to LKB1, thereby inhibiting the antiinflammatory effects of AMPK activation.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2011.00401
*J-MT and H-BB contributed equally to this work.
Address correspondence to Jaroslaw Zmijewski, Department of Medicine University of Ala-
bama at Birmingham School of Medicine, 901 19th Street South, BMRII, Room 304, Birming-
ham, AL 35294. Phone: 205-934-7793; Fax: 205-934-7437; E-mail: zmijewsk@uab.edu.
Submitted October 19, 2011; Accepted for publication March 1, 2012; Epub
(www.molmed.org) ahead of print March 2, 2012.
 metabolism, recent studies have shown
that AMPK activation also has potent
antiinflammatory effects in multiple cell
populations, including neutrophils,
macro phages and endothelial cells
(11–15). For example, AMPK suppressed
production of nuclear factor (NF)-κB–
 dependent cytokines in TLR4-stimulated
cells (11,14). Treatment of mice with 
5-aminoimidazole-4-carboxamide-1-β-D-
ribofuranoside (AICAR) or metformin,
two inducers of AMPK activation, re-
duced the severity of lipopolysaccharide
(LPS)-induced acute inflammatory lung
injury (11,16). However, there is little ev-
idence that AMPK is activated in inflam-
matory states, such as acute lung injury,
despite the presence of conditions in-
cluding increased release of reactive
oxygen species and diminished genera-
tion of ATP, which would be expected to
 result in AMPK activation (9,17–19).
Therefore, a potentially important, and
presently unanswered question, relates
to the mechanisms that may prevent ac-
tivation of AMPK in such conditions.
In the present experiments, we ex-
plored potential mechanisms by which in-
duction of cellular activation through
TLR4 may modulate AMPK activation.
We found that engagement of TLR4 inhib-
ited activation of AMPK and also resulted
in increased cytoplasmic interactions be-
tween high mobility group box 1 protein
(HMGB1) and liver kinase B1 (LKB1), a
kinase directly upstream to AMPK, in iso-
lated cell populations and under in vivo
conditions in the lungs of LPS-treated
mice. Overexpression of HMGB1 sup-
pressed AMPK activation, whereas the
opposite effect was observed in cells in
which HMGB1 was knocked down with
small interfering RNA (siRNA). These
findings provide new insights into mech-
anisms by which AMPK activation is reg-
ulated during inflammatory responses.
MATERIALS AND METHODS
Mice
Male C57BL/6 mice were purchased
from the National Cancer Institute (Fred-
erick, MD, USA). Male mice, 8–12 wks
old, were used for experiments. The mice
were kept on a 12:12-hour light–dark
cycle with free access to food and water.
All experiments were conducted in ac-
cordance with institutional review
board–approved protocols (University of
Alabama at Birmingham Institutional
Animal Care and Use  Committee).
Reagents
RPMI 1640 was purchased from
BioWhittaker (Walkersville, MD, USA).
Fetal bovine serum (FBS) and penicillin-
streptomycin were obtained from Gemini
Bioproducts (Calabasas, CA, USA).
AICAR was purchased from Enzo Life Sci-
ence (Plymouth Meeting, PA, USA). Anti-
bodies against total and phosphorylated
Thr172-AMPK and Ser79-acetyl-CoA car-
boxylase (ACC) and total LKB1 were pur-
chased from Cell Signaling Technology
(Beverly, MA, USA), whereas antibody to
calcium/calmodulin-dependent protein
kinase kinase (CaMKK) was purchased
form Abcam (Cambridge, MA, USA). Cus-
tom antibody mixtures and negative selec-
tion columns for neutrophil isolation were
purchased from Stem Cell Technologies
(Vancouver, British Columbia, Canada).
Culture medium, scrambled siRNA and
siRNA to the HMGB1 were purchased
from Thermo Scientific/Dharmacon (St.
Louis, MO, USA). ANTI-FLAG® M2 mon-
oclonal antibody and affinity agarose,
tubulin and histone deacetylase (HDAC)
antibodies and hydrogen peroxide were
purchased from Sigma-Aldrich (St. Louis,
MO, USA). Alexa Fluor 594– conjugated
phalloidin and Alexa Fluor 488–labeled
secondary antibodies were purchased
from Invitrogen (Carlsbad, CA, USA).
Mouse monoclonal anti-HMGB1 antibody
was obtained from R&D Systems (Minne-
apolis, MN, USA).
Neutrophil and Macrophage Isolation
and Culture
Bone marrow neutrophils were puri-
fied using a negative selection column
purification system, as previously de-
scribed (16,20). Briefly, bone marrow cell
suspensions were isolated from the femur
and tibia of a mouse by flushing with
RPMI 1640 medium with 5% FBS. The
cell suspension was passed through a
glass wool column and collected by sub-
sequent washing with phosphate-
buffered saline (PBS) containing 5% FBS.
Negative selection to purify neutrophils
was performed by incubation of the cell
suspension with biotinylated primary an-
tibodies specific for the cell surface mark-
ers F4/80, CD4, CD45R, CD5 and TER119
(StemCell Technologies, Vancouver, BC,
Canada; http://www.stemcell.com) for
15 min at 4°C followed by incubation
with anti- biotin tetrameric antibodies
(100 μL; StemCell Technologies) for
15 min. The complex of anti-tetrameric
antibodies and cells was then incubated
with colloidal magnetic dextran iron par-
ticles (60 μL; StemCell Technologies) for
an  additional 15 min at 4°C. The T cells,
B cells, red blood cells, monocytes and
macrophages were captured in a column
surrounded by a magnet, allowing the
neutrophils to pass through. Neutrophil
purity, as determined by Wright-Giemsa–
stained cytospin preparations, was con-
sistently >98. Viability of purified bone
marrow neutrophils was determined
after trypan blue staining and was con-
sistently >95%. In selected experiments,
neutrophil viability was also determined
using annexin/prodidium iodide (PI)
staining and flow cytometry. Peritoneal
macrophages were elicited in 8- to 10-
wk-old mice using Brewer thioglycollate
(24). Cells were collected 5 d after in-
traperitoneal injection of thioglycollate.
Macrophages were then cultured in 12-
well plates (105 cells/well) in RPMI 1640
medium containing 10% FBS at 37°C.
Nonadherent cells were removed by
washing cells after 1 h of culture.
Expression of HMGB1-FLAG in MCF7
Cells
A human breast adenocarcinoma cell
line (MCF7) cell line that inducibly ex-
presses HMGB1-FLAG (MCF7-HMGB1-
FLAG) was generated as described previ-
ously (21). The MCF7-HMGB1-FLAG cell
line was maintained in RPMI 1640 media,
supplemented with 10% FBS  (Atlanta Bio-
logicals), penicillin (100 U/mL) and strep-
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tomycin (100 ng/mL) at 37°C, 5% CO2. To
induce expression of HMGB1-FLAG,
~80% confluent cells grown in 12-well
plates were incubated with doxycycline 
(1 μg/mL) for 24 h. The amount of ex-
pressed HMGB1-FLAG was then deter-
mined using Western blot analysis.
Western Blot Analysis
Western blot analysis was performed as
previously described (9,22). Briefly, cell
lysates of neutrophils (3.5 × 106/ well),
macrophages (2 × 105/well) or MCF7 cells
(105/well) were prepared using lysis buffer
containing Tris pH 7.4 (50 mmol/L), NaCl
(150 mmol/L), Nonidet P40 (NP-40) (0.5%,
vol/vol), ethylenediaminetetraacetic acid
(EDTA) (1 mmol/L), ethyleneglycotetra -
acetic acid (EGTA) (1 mmol/L), okadaic
acid (1 nmol/L) and protease inhibitors.
Lysis buffer was also used to prepare lung
homogenates, as described previously
(11). Cell lysates or lung homogenates
were sonicated and then centrifuged at
10,000g for 15 min at 4°C to remove insol-
uble material. The protein concentration
in the supernatants was determined using
the Bradford reagent (Bio-Rad) with
bovine serum acid (BSA) as a standard.
Samples were mixed with Laemmli sam-
ple buffer and boiled for 5 min. Equal
amounts of proteins (50 μg/sample) were
resolved by 8% sodium dodecyl
sulfate–polyacryla mide gel electrophore-
sis and transferred onto polyvinylidene
fluoride membranes (Immobilon P; Milli-
pore, Billerica, MA, USA). The mem-
branes were probed with specific antibod-
ies as described in the figure legends
followed by detection with horseradish
peroxidase–conjugated goat anti-rabbit
IgG. Bands were visualized by enhanced
chemiluminescence (Super Signal; Pierce
Biotechnology, Rockford, IL, USA) and
quantified by  AlphaEaseFC software
(Alpha Innotech, San Leandro, CA, USA).
Each experiment was carried out two or
more times using cell populations ob-
tained from separate groups of mice.
siRNA Knockdown of HMGB1
Murine macrophagelike RAW 264.7 cells
were incubated with 2 μmol/L scrambled
siRNA or siRNA specific to HMGB1 as de-
scribed previously (23,24). Briefly, cells 
(3 × 105/ well) in 24-well plates were incu-
bated in Accell media with scrambled
siRNA (2 μmol/L) or siRNA (2 μmol/L) to
HMGB1 for 72 h. Cells were treated as de-
scribed in the figure legends and then sub-
jected to immunoprecipitation and West-
ern blot analysis as indicated.
Imaging HMGB1 in Macrophages
Cells were incubated with 4% para -
formaldehyde in PBS for 20 min at room
temperature and then washed with PBS
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Figure 1. TLR4 engagement diminishes AMPK activation. Bone marrow neutrophils (A, B, D
and E) or RAW 274.7 macrophages (F, G, H and I) were treated with LPS (0 or 100 ng/mL) for
4 h followed by culture with AICAR (0, 100, 250, 500 or 1,000 μmol/L) for an additional 90 min
or H2O2 (0, 100, 150, 200 or 250 μmol/L) for 45 min, as indicated. Representative Western blots
and mean optical densitometry show amount of AMPK, phospho-Thr172AMPKα, ACC, phos-
pho-Ser79ACC and actin. Data are means ± standard deviation (SD). Two independent
experiments were performed. (C) Average of AMP-to-ATP ratio in neutrophils cultured with
or without LPS (100 ng/mL) for 4 h (means ± SD, n = 4 independent experiments, *P < 0.05).
and permeabilized with 0.1% TritonX-
100/PBS for 4 min. The cells were then
washed and incubated with 3% BSA in
PBS for 45 min, followed by addition of
anti-HMGB1 antibody overnight at 4°C.
Next, cells were washed with PBS and
then incubated with Alexa Fluor 488– -
labeled secondary antibody and Alexa
Fluor 594–conjugated phalloidin for 90
and 20 min, respectively, at room temper-
ature. After washing with PBS, the cells
were mounted with emulsion oil  solution
containing 4′,6-diamidino-2-phenylindole
(DAPI) to visualize nuclei. Confocal mi-
croscopy was performed as previously
described (24) using a confocal laser scan-
ning microscope (model LSM 710 confo-
cal microscope; Carl Zeiss MicroImaging,
Jena, Germany) provided by the High-
 Resolution  Imaging Facility at the Uni-
versity of  Alabama at  Birmingham.
Purification of Cytosolic and Nuclear
Fractions
Separation of nuclear and cytosolic
fractions was carried out as described pre-
viously (25). The cells were washed with
PBS, and 500 μL lysis buffer was added
(10 mmol/L Tris, pH 7.5, 10 mmol/L
NaCl, 3 mmol/L MgCl2, 0.05% NP-40, 
1 mmol/L EGTA, 1 mmol/L sodium or-
thovanadate, 50 mmol/L sodium fluoride
and protease inhibitors) was added.
Lysed cells were centrifuged (2,700g) for
10 min at 4°C. The cytosol-containing su-
pernatants were then centrifuged at
20,800g for an additional 15 min at 4°C to
obtain the  cytosolic fraction. The pellet-
containing nuclei was washed three times
(wash buffer: 10 mmol/L PIPES, pH 6.8,
300 mmol/L sucrose, 3 mmol/L MgCl2,
1 mmol/L EGTA, 25 mmol/L NaCl,
1 mmol/L sodium orthovanadate,
50 mmol/L sodium fluoride and protease
inhibitors) and centrifuged at 2,700g for 
5 min at 4°C. The nuclear pellet was sus-
pended in 100 μL wash buffer, layered
over a cushion of 1 mL sucrose buffer 
(1 mol/L sucrose, 1 mmol/L sodium or-
thovanadate, 50 mmol/L sodium fluoride
and protease inhibitors) and centrifuged
at 2,700g for 10 min. The pellet-containing
nuclei were washed with 100 μL wash
buffer and centrifuged at 2,700g for 5 min
at 4°C to remove residual sucrose buffer.
Nuclear proteins were extracted by incu-
bation of purified nuclei with lysis buffer
for 30 min at 4°C. To remove insoluble
material, the extract was centrifuged at
16,000g for 10 min at 4°C. Western blot
analyses of subcellular fractions were per-
formed using 60 μg protein obtained from
cytosolic and 5 μg protein from nuclear
fractions. Purity of obtained fractions was
determined by reprobing the membranes
with antibody to tubulin and HDAC, as
indicated in the figure legends.
Coimmunoprecipitation Assays
Cell extracts or lung homogenates
(350 μg/mL) prepared in immunopre-
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Figure 2. Translocation of HMGB1 from nucleus to cytosol is associated with diminished
AMPK activation in LPS-stimulated macrophages. (A) Representative images show time-de-
pendent accumulation of HMGB1 in the cytosol after culture of RAW 274.7 macro phages
with LPS (100 ng/mL) for 0, 2 or 4 h. (B) Western blots show amounts of HMGB1, phospho-
and total AMPK, and tubulin or HDAC in whole cell extracts as well as cytosolic or nuclear
fractions obtained from RAW 264.7 macrophages incubated with LPS (100 ng/mL) for 0, 1, 2
or 4 h. (C) Mean band optical density of phospho-AMPK/AMPK and total HMGB1 in cytoso-
lic fractions of macrophages treated as described in (B). Data are means ± SD. Two inde-
pendent experiments provided similar results.
cipitation buffer (26) were incubated
with anti-AMPK, -LKB1 or -CaMKKβ
antibodies (2 μg/mL) overnight at 4°C.
Samples were then incubated with pro-
tein-A agarose (25 μL/sample) for an ad-
ditional 60 min at 4°C. The protein-A
agarose conjugates were then washed
with immunoprecipitation buffer. The
amount of HMGB1 associated with
AMPK, LKB1 or CaMKKβ was deter-
mined by probing of the Western blot
membrane with specific antibodies. In
selected experiments, cell extracts ob-
tained from the MCF7-HMGB1-FLAG
cell line were incubated with ANTI-
FLAG® M2 beads for 60 min at 4°C. The
beads were then washed with immuno-
precipitation buffer four times, and the
amounts of HMGB1-FLAG associated
with LKB1 were determined using West-
ern blot analysis.
Acute Lung Injury Model
Acute lung injury was induced by in-
tratracheal administration of 1 mg/kg
LPS in 50 μL PBS as previously described
(16,20,27,28). With this model, acute lung
injury is characterized by neutrophil in-
filtration into the lung interstitium and
airways, development of interstitial
edema and increased pulmonary proin-
flammatory cytokine production, with
the greatest degree of injury being pres-
ent 24 h after LPS exposure (11). Briefly,
mice were anesthetized with isoflurane,
the tongue was gently extended and LPS
in PBS or PBS alone (control) was de-
posited into the pharynx (53). Lungs
were harvested 24 h after LPS adminis-
tration, and homogenates were prepared
using buffer containing Tris pH 7.4 
(50 mmol/L), NaCl (150 mmol/L), NP-40
(0.5%, vol/vol), EDTA (1 mmol/L), EGTA
(1 mmol/L), okadaic acid (1 nmol/L) and
protease inhibitors. Of note, lungs were
flushed with PBS to remove circulating
cells before harvesting (lungs were not
subjected to bronchoalveolar lavage
[BAL] acquisition). Lung homogenates
were then sonicated on ice for 90 s and
centrifuged (16,000g for 10 min at 4°C),
and protein concentration was deter-
mined using the Bradford assay.
Statistical Analysis
Statistical significance was determined
by the Wilcoxon rank-sum test (indepen-
dent two- group Mann-Whitney U test)
as well as the Student t test for compar-
isons between two groups. Multigroup
comparisons were performed using one-
way ANOVA with the Turkey post hoc
test. A value of P < 0.05 was considered
significant. Analyses were performed on
SPSS version 16.0 for Windows.
All supplementary materials are available
online at www.molmed.org.
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Figure 3. Effects of HMGB1 expression on AMPK activity. (A–D) The amounts of phosphory-
lated AMPK, ACC, total AMPK, ACC, HMGB1 and HMGB1-FLAG were determined in MCF7-
HMGB1 cells incubated without (–DOX) or with doxycycline (+DOX) for 24 h followed by
exposure to AICAR (A, B) or H2O2 (C, D) for 1 h. Representative Western blots are shown.
The amount of phospho-AMPK and phospho-ACC (B, D) were obtained from three inde-
pendent experiments (means ± SD, *P < 0.05, **P < 0.01, ***P < 0.001).
RESULTS
TLR4 Engagement Inhibits Activation
of AMPK
Activation of AMPK inhibits TLR4-
 induced activation of neutrophils or
macrophages, including NF-κB activa-
tion and cytokine production (11,13,29).
However, little is known about how in-
flammatory stimuli, such as TLR4 en-
gagement, may affect AMPK activation.
To address this question, neutrophils
were incubated with or without LPS
(100 ng/mL) for 4 h followed by expo-
sure to the AMPK activator AICAR for
an additional 90 min. As shown in
 Figures 1A and C, AICAR dose-depend-
ently increased phosphorylation of
AMPK and phosphorylation of ACC, a
downstream target of AMPK. In contrast,
pretreatment with LPS resulted in de-
creased activation of AMPK by AICAR.
Such diminished AICAR- dependent acti-
vation of AMPK may result from the en-
zymatic conversion of AICAR to ZMP
(5′-phosphorylated form of AICAR) in
LPS-treated cells, thereby reducing the
ability of AICAR to affect AMPK (30).
However, similar inhibitory effects of
LPS treatment on AMPK activation 
were found in neutrophils cultured with
H2O2, a direct activator of AMPK (Fig-
ures 1B, D) (9). There was no significant
difference between the viability of con-
trol (untreated) neutrophils and neu-
trophils treated with the combination of
LPS and AICAR or LPS and H2O2.
We determined if alterations in the
ATP-to-AMP ratio in neutrophils cul-
tured with LPS were responsible for the
lack of activation of AMPK under such
conditions. In particular, if the ATP-to-
AMP ratio increased after LPS exposure,
this could explain the diminished ability
of AICAR or H2O2 to activate AMPK.
However, as shown in Figure 1E, the
ATP-to-AMP ratio decreased after cul-
ture of neutrophils with LPS. Although
such change in the ATP-to-AMP ratio
should promote AMPK activation, West-
ern blot analysis revealed that neither
LPS alone nor subsequent exposure of
LPS-stimulated cells to AICAR or H2O2
potentiated phosphorylation of AMPK
or ACC. Of note, such inhibitory effects
of TLR4 engagement on AMPK activa-
tion were not limited to neutrophils,
since pretreatment of RAW 264.7 macro -
phages with LPS also diminished activa-
tion of AMPK by AICAR or H2O2. Simi-
larly to our findings obtained with
neutrophils or cell lines, exposure to LPS
diminished the ability of peritoneal
macrophages to activate AMPK after
culture with AICAR or H2O2 (Supple-
mentary Figure S1).
Time-Dependent Changes in the
Nuclear to Cytosol Translocation of
HMGB1 Correlate with the Diminished
Activation of AMPK in LPS-Treated
Macrophages
HMGB1 is almost exclusively located
in the nucleus of unstimulated cells (Fig-
ure 2A) but demonstrates time-depen-
dent translocation from the nucleus to
cytosol after culture of macrophages
with LPS. The cytosolic accumulation of
HMGB1 in LPS-stimulated RAW 264.7
macrophages was confirmed using cell
fractionation and Western blot analysis
(Figure 2B). These results indicated that
modest accumulation of HMGB1 was
found in the cytosol after LPS exposure,
while most of the HMGB1 was retained
in the nucleus. However, a time-depen-
dent increase in cytosolic HMGB1 in
LPS-stimulated macrophages was associ-
ated with decreased phosphorylation of
AMPK. Although AMPK can be readily
detected in the nucleus, exposure of cells
to LPS did not affect AMPK phosphory-
lation in this compartment, indicating
that the diminished phosphorylation of
AMPK in TLR4-activated macrophages
was primarily a cytoplasmic event.
Ectopic Expression of HMGB1
Diminishes AMPK Activation
Although the above experiments
showed an inverse correlation in TLR4-
stimulated macrophages between
HMGB1 translocation to the cytoplasm
and decrease in AMPK phosphoryla-
tion, they did not establish whether
HMGB1 was directly involved in the in-
hibition of AMPK phosphorylation that
occurred in these cells. This issue was
examined using MCF7 cells that in-
ducibly express FLAG-tagged HMGB1
(21). Under control conditions, the
amounts of HMGB1-FLAG were unde-
tectable, whereas doxycycline treatment
resulted in upregulation of HMGB1-
FLAG (Figure 3A). As shown in Figure
3, exposure to AICAR or H2O2 resulted
in robust activation of AMPK in control
MCF7 cells (–DOX), whereas only a
modest increase in the phosphorylation
of AMPK and ACC was found in
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Figure 4. Diminished expression of HMGB1 increases AMPK activity. (A, B) RAW 264.7 cells
were treated with HMGB1-specific siRNA or control scrambled siRNA and then incubated
with or without AICAR (1 mmol/L) for 1 h. Representative Western blots (A) and bend opti-
cal densitometry (B) show the levels of phosphorylated AMPK and ACC, as well as total
AMPK, ACC and HMGB1 (means ± SD, n = 3, *P < 0.05, **P < 0.01). ns, Nonsignificant.
 doxycycline-treated cells that expressed
HMGB1-FLAG (+DOX).
We next determined whether knock-
down of HMGB1 affects the activation of
AMPK. Treatment of RAW 264.7 macro -
phages with HMGB1-specific siRNA de-
creased HMGB1 levels compared with
cells treated with nonspecific siRNA
(Figure 4). Knockdown of HMGB1 re-
sulted in increased AMPK phosphoryla-
tion as well as enhanced activation of
AMPK after culture of the macrophages
with AICAR. These results show that
HMGB1 is directly involved in regulat-
ing AMPK activity, as enhanced expres-
sion of HMGB1 diminished, whereas
knockdown of HMGB1 increased AMPK
activation.
TLR4 Engagement Increases Complex
Formation between HMGB1 and LKB1
To explore whether the inhibitory ef-
fects of HMGB1 on AMPK activation are
due to interactions between HMGB1 and
AMPK subunits and/or with kinases up-
stream of AMPK, including LKB1 or
CaMKK, RAW 264.7 macrophages were
incubated with or without LPS, and then
interactions between AMPKα1, LKB1,
CaMKKβ and HMGB1 were examined.
As shown in Figure 5A, TLR4 engage-
ment resulted in marked increase of
HMGB1-LKB1 complex formation, com-
pared with only slight enhancement of
interactions between HMGB1 and
AMPKα1 or CaMKKβ. The ability of
HMGB1 to bind LKB1 was further con-
firmed using MCF7 cells that inducibly
express HMGB1-FLAG (Figure 5B).
These results suggest that a potential
mechanism by which HMGB1 inhibits
AMPK activation may be through en-
hanced interactions with LKB1, thereby
preventing LKB1-induced activation of
AMPK.
AMPK Activity Is Decreased in Lungs
of Mice with LPS-Induced Acute Lung
Injury
To determine if LPS exposure also in-
hibits AMPK activation in vivo, phospho-
rylation of AMPK and ACC was deter-
mined in lung homogenates obtained
24 h after LPS administration. As shown
in Figure 6A, whereas a significant in-
crease in AMP-to-ATP ratios was found
in the lungs of LPS-treated mice, there
was a modest decrease in the phosphory-
lation of AMPK and a significant de-
crease in the levels of phospho-ACC
(Figures 6B–D). These results are consis-
tent with our in vitro data using TLR4-
stimulated cells (Figure 1E). Similar to
 results obtained in vitro, immunoprecipi-
tation of LKB1 from the lungs of LPS-
treated mice showed increased interac-
tions between HMGB1 and LKB1.
DISCUSSION
The present results show that TLR4-
 induced stimulation of neutrophils or
macrophages is associated with inhibi-
tion of AMPK activation. In particular,
we found that culture of macrophages
with LPS decreased the ability of two po-
tent activators of AMPK (AICAR and
H2O2) to efficiently promote phosphory-
lation of AMPK and ACC, a downstream
target of AMPK. Furthermore, whereas a
significant increase in intracellular AMP-
to-ATP ratios was found after culture of
neutrophils with LPS, a situation that
should result in increased AMPK activity,
AMPK activation was not altered (11,16).
Although TLR4 engagement can poten-
tially affect AMPK activation by inhibit-
ing enzymatic conversion of AICAR to
ZMP, a similar inhibition of AMPK acti-
vation was found in LPS-stimulated cells
that were then treated with H2O2, com-
pared with cells treated with H2O2 alone.
Of note, previous studies have shown
that H2O2 can activate AMPK both as a
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Figure 5. Stimulation with LPS or overexpression of HMGB1 enhances interactions between
HMGB1 and LKB1. (A) RAW 264.7 macrophages were treated with LPS (0 or 100 ng/mL) for
4 h, and then cell extracts were subjected to immunoprecipitation using antibodies to
LKB1, AMPK or CAMKK. Representative Western blots and quantitative analysis show
amounts of HMGB1 associated with LKB1, AMPK or CAMKK after immunoprecipitation (left
panel) as well as total HMGB1, CAMKK, AMPK and LKB1 in cell extracts before (right
panel) immunoprecipitation (means ± SD, n = 3, ***P < 0.001). (B) Complex formation be-
tween HMGB1 and LKB1 was determined in control MCF7-HMGB1 cells (–DOX) or after
doxycycline-induced expression of HMGB1-FLAG (+DOX). Cell extracts were subjected to
immunoprecipitation with ANTI-FLAG® M2 monoclonal antibody followed by Western blot
analysis of LKB1. Representative blots show amounts of LKB1 after HMGB1-FLAG pull-down
(left panel) as well as before immunoprecipitation (right panel). A second independent
experiment provided similar results.
result of increasing intracellular AMP/
ATP levels as well as through additional
mechanisms, including direct oxidative
modification of the AMPKα1 subunit
(9,31,32). Our results indicate that,
whereas exposure of cells to H2O2
and/or an increase in the AMP-to-ATP
ratio normally robustly activates AMPK,
such activation is inhibited in TLR4-
 stimulated cells. Previous studies (11,16)
have shown that AMPK can be effec-
tively activated before TLR4 engagement
and also that AMPK activation dimin-
ished proinflammatory response of neu-
trophils, macrophages and endothelial
cells, including release of HMGB1 after
exposure of macrophages to LPS. How-
ever, our current studies demonstrated
that the ability of cells to activate AMPK
is diminished after exposure to LPS. In
particular, a significant decrease, but not
complete inhibition, of AMPK activation
was found when cells were first cultured
with LPS before treatment with AICAR
or H2O2. These results suggest that coun-
terregulatory mechanisms affect the acti-
vation of AMPK in LPS-treated cells.
HMGB1 is a 215–amino acid nuclear
protein with highly conserved sequence
among species. Although the initial func-
tion described for HMGB1 was as a nu-
clear protein involved in regulating gene
expression (33,34), HMGB1 has been
shown to be released from injured and
dying cells and actively secreted by stim-
ulated macrophages (35–38). Extracellu-
lar HMGB1 has potent proinflammatory
actions and contributes to inflammation
through several mechanisms, including
by enhancing cellular activation induced
through Toll-like receptors, including
TLR2, TLR4 and TLR9, or via the recep-
tor for advanced glycation end products
(RAGE) (39–41). HMGB1 has also been
shown to enhance neutrophil chemotaxis
and to diminish the uptake and clear-
ance of apoptotic cells by macrophages
and other phagocytes (42, 43). Increased
circulating concentrations of HMGB1 
are present in septic patients, as well 
as in animal models of endotoxemia,
hemorrhage/ ischemia and sepsis (44–46).
Neutralization of HMGB1 with specific
antibodies diminished mortality in
murine endotoxemia and sepsis and also
decreased pulmonary injury associated
with sepsis, hemorrhage or experimental
arthritis (46–49).
Although nuclear to cytoplasmic
translocation of HMGB1 is a well-known
event in TLR4-stimulated cells, associa-
tion between this event and AMPK
 activation has not previously been de-
scribed. In the present studies, we found
an inverse relationship between accumu-
lation of HMGB1 in the cytoplasm of
LPS-stimulated macrophages and AMPK
phosphorylation, suggesting that
HMGB1 might be involved in the sup-
pression of the ability of AMPK to be ac-
tivated in TLR4-activated cells. In our ex-
periments, overexpression of HMGB1
diminished, whereas knockdown of
HMGB1 increased, AMPK activity. Re-
cent studies have shown that stimulation
of macrophages with LPS is associated
with inhibition of LKB1 activation, a ki-
nase upstream to AMPK (50). In the pres-
ent studies, we found enhanced LKB1-
HMGB1 complex formation in MCF7
cells that overexpressed HMGB1, in
macrophages incubated with LPS and in
the lungs of LPS-treated mice. Such find-
ings provide important insights into the
mechanism by which HMGB1 may affect
AMPK activation; in particular, because
LKB1 plays an important role in AMPK
activation by AICAR and hydrogen per-
oxide (51–54), increased interactions
 between LKB1 and HMGB1 after TLR4-
 induced cellular activation, with con-
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Figure 6. Lack of AMPK activation, despite increase in AMP-to-ATP ratio, in the lungs of
LPS-treated mice. The amounts of AMP, ATP (A) and phosphorylation of AMPK and ACC
(B–D) were determined in lung homogenates obtained from mice given saline or LPS
(1 mg/kg) intratracheally 24 h previously. Representative Western blots (B) and quantita-
tive data (C and D) are shown (mean ± SD, n = 6, *P < 0.05 compared with control mice).
(E) Representative Western blots show the amounts of LKB1 and of HMGB1 in whole lung
homogenates after immunoprecipitation of LKB1 from lung homogenates of control and
LPS-treated mice (three mice per group).
comitant inhibition of interactions
 between LKB1 and AMPK, may be re-
sponsible for suppression of AMPK acti-
vation under such conditions.
As observed in macrophages and neu-
trophils after culture with LPS, there was
a decrease in the phosphorylation of
AMPK and also of ACC, an important
downstream target of AMPK, in the
lungs of LPS-treated mice, despite in-
creased AMP-to-ATP ratios—an event
that would be expected to activate
AMPK in a potent manner. Enhanced
generation of ROS has been shown to
occur in the lungs during LPS-induced
acute lung injury (55–58) and also should
result in AMPK activation. However, de-
spite such potent inducing factors for
AMPK activation, we did not find any
evidence that AMPK was activated in the
lungs of LPS-treated mice. Such results
are consistent with the finding that
AMPK is not activated in the lungs of
patients with acute lung injury, despite
reduced ATP levels and increased pro-
duction of ROS being present under such
conditions (57–59). Consistent with the
results obtained from cultured cells, en-
hanced interaction between HMGB1 and
LKB1 was found in the lungs of mice
with LPS-induced acute lung injury.
HMGB1 has been shown to have po-
tent proinflammatory activity and to con-
tribute to organ injury during inflamma-
tory processes initiated by infectious and
noninfectious etiologies (39). Unlike the
proinflammatory properties of HMGB1,
activation of AMPK has antiinflamma-
tory effects and has been shown to de-
crease proinflammatory cytokine produc-
tion by LPS-stimulated macro phages and
neutrophils, as well as diminish organ in-
jury after LPS-induced lung inflamma-
tion, sepsis, hemorrhage and ischemic
cardiovascular events (11,16,60,61).
CONCLUSION
Our present findings suggest a novel
mechanism by which HMGB1 may con-
tribute to enhancing inflammatory
processes. In particular, by inhibiting ac-
tivation of AMPK through complex for-
mation with LKB1, an upstream activator
of AMPK, HMGB1 may suppress antiin-
flammatory regulatory events that nor-
mally would diminish tissue injury in-
duced by TLR4 engagement and
probably by other mediators capable of
producing inflammation. Our findings
demonstrating the ability of HMGB1 to
prevent AMPK activation suggest that
therapeutic approaches that inhibit
translocation of HMGB1 from the nu-
cleus to the cytoplasm and/or prevent
interactions between LKB1 and HMGB1
may be beneficial in acute and chronic
inflammatory conditions, such as sepsis
and rheumatoid arthritis, pathophysio-
logic states in which HMGB1 plays a
contributory role (62–64). Of note, nonse-
lective blockade of the intracellular ac-
tions of HMGB1 are unlikely to be effica-
cious given the important transcriptional
functions of HMGB1 (33,65). Because
binding between HMGB1 and inflamma-
tory mediators, including LPS, potenti-
ates their ability to activate cells through
TLR-dependent mechanisms (66), thera-
peutic approaches to neutralize circulat-
ing HMGB1 may also restore the antiin-
flammatory actions of AMPK through
preventing TLR4-induced inhibition of
AMPK activation.
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